AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17454835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no carbohydrate drink)
Number of subjects: 18
Study 15026831 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 10
Study 15026831 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (CON)
Number of subjects: 10
Study 11174230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual hyoscyamine sulfate (0.125 mg) with ketorolac tromethamine (30 mg IV)
Number of subjects: 43
Study 11174230 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ketorolac tromethamine (30 mg IV)
Number of subjects: 43
Study 9670686 — intervention group
Group type: EXPERIMENTAL
Intervention: Laferon therapy as part of complex treatment schemes
Number of subjects: 0
Study 9670686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8149520 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA
Number of subjects: 1473
Study 8149520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1473
Study 8149520 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1473
Study 8149520 — intervention group
Group type: COMPARATOR
Intervention: Early conservative strategy
Number of subjects: 1473
Study 2458219 — intervention group
Group type: EXPERIMENTAL
Intervention: Product A (Procan‐SR)
Number of subjects: 10
Study 2458219 — intervention group
Group type: COMPARATOR
Intervention: Product B (Pronestyl‐SR)
Number of subjects: 10
Study 2458219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 10
Study 2458219 — intervention group
Group type: EXPERIMENTAL
Intervention: Product A to Product B switch
Number of subjects: 10
Study 31437865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 56
Study 31437865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg
Number of subjects: 56
Study 31437865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 200 mg
Number of subjects: 56
Study 31437865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 400 mg
Number of subjects: 56
Study 31437865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg (multiple doses)
Number of subjects: 56
Study 31437865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 200 mg (multiple doses)
Number of subjects: 56
Study 31437865 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg (control)
Number of subjects: 56
Study 29570740 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-worn accelerometer
Number of subjects: 141
Study 29570740 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn accelerometer
Number of subjects: 141
Study 29570740 — intervention group
Group type: COMPARATOR
Intervention: Automated DT algorithm
Number of subjects: 141
Study 26498603 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h magnesium sulfate therapy (4 g loading dose followed by 1 gm/h infusion for 6 h)
Number of subjects: 119
Study 26498603 — intervention group
Group type: COMPARATOR
Intervention: 24-h conventional magnesium sulfate therapy (4 g loading dose followed by 1 gm/h infusion for 24 h)
Number of subjects: 119
Study 25379838 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point Balanced Equal-Interval
Number of subjects: 216
Study 25379838 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point Positive-Packed
Number of subjects: 216
Study 25379838 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point Positive-Centered Equal-Interval
Number of subjects: 216
Study 21766483 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise (12 weeks)
Number of subjects: 122
Study 21766483 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study 19926370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus, mycophenolate mofetil, and prednisone
Number of subjects: 127
Study 19926370 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine, mycophenolate mofetil, and prednisone
Number of subjects: 127
Study 17400979 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Broncho-Cath R-DLT
Number of subjects: 80
Study 17400979 — intervention group
Group type: COMPARATOR
Intervention: Standard Broncho-Cath R-DLT
Number of subjects: 80
Study 15448985 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5-20 mg/day, with over 95% receiving 5 or 10 mg/day)
Number of subjects: 0
Study 12375486 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling
Number of subjects: 174
Study 12375486 — intervention group
Group type: COMPARATOR
Intervention: In-class enrichment program
Number of subjects: 174
Study 10476344 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and 5 alpha‐dihydrotestosterone
Number of subjects: 46
Study 8760846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tip‐Edge bracket system
Number of subjects: 12
Study 8760846 — intervention group
Group type: COMPARATOR
Intervention: A‐Company straight wire bracket system
Number of subjects: 12
Study 1761174 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of metronidazole (500 mg vaginal suppository) before hysterectomy
Number of subjects: 242
Study 1761174 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metronidazole prophylaxis)
Number of subjects: 242
Study 7043104 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-reduction treatment program with diet instruction and weekly meetings with a dietitian for 16 months
Number of subjects: 0
Study 7043104 — intervention group
Group type: COMPARATOR
Intervention: Control group received only diet instruction
Number of subjects: 0
Study 7043104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups made successful changes in behavior resulting in seemingly permanent reductions in weight
Number of subjects: 0
Study 7043104 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation through triceps skinfold measurements, parents' questionnaire, and structured interview
Number of subjects: 0
Study 30762156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bringing in the Bystander‐High School Curriculum (BITB‐HSC)
Number of subjects: 2403
Study 30762156 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no BITB‐HSC)
Number of subjects: 2403
Study 27979041 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care (pharmacologic or electrical cardioversion)
Number of subjects: 437
Study 27979041 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see approach (rate control medication until spontaneous conversion, with possible cardioversion within 48 hours)
Number of subjects: 437
Study 27979041 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care
Number of subjects: 437
Study 27979041 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see approach
Number of subjects: 437
Study 25945079 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute magnesium supplementation (300 mg/d for 1 week)
Number of subjects: 13
Study 25945079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic magnesium supplementation (300 mg/d for 4 weeks)
Number of subjects: 13
Study 23329006 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate adenoidectomy
Number of subjects: 111
Study 23329006 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 111
Study 22109781 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT)
Number of subjects: 40
Study 22109781 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 40
Study 19122548 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (n = 96): intravenous loading dose of 10 microg kg(‐1) butorphanol followed by infusion of 2 microg kg(‐1) h(‐1) butorphanol combined with intravenous PCA set at a bolus of 0.02 mg kg(‐1) morphine
Number of subjects: 186
Study 19122548 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (n = 96)
Number of subjects: 186
Study 17329511 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor at 41 weeks
Number of subjects: 508
Study 17329511 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (antenatal fetal surveillance every third day)
Number of subjects: 508
Study 15352914 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg on-demand
Number of subjects: 774
Study 15352914 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg continuous
Number of subjects: 774
Study 11434941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 10% (1.5 ml/min)
Number of subjects: 8
Study 11434941 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 8
Study 9887454 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year therapy
Number of subjects: 60
Study 8556965 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg p.o. daily
Number of subjects: 59
Study 8556965 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg p.o. bid
Number of subjects: 59
Study 8556965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 2307923 — intervention group
Group type: EXPERIMENTAL
Intervention: Interns after 1 year of clinical experience
Number of subjects: 0
Study 2307923 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced clinicians
Number of subjects: 0
Study 7351166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurokeratinate (Auro-Detoxin) administered intramuscularly at slowly rising doses
Number of subjects: 0
Study 7351166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurokeratinate (Auro-Detoxin) at 25 mg gold twice weekly
Number of subjects: 0
Study 7351166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurokeratinate (Auro-Detoxin) at 65 mg gold once a month
Number of subjects: 0
Study 7351166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurokeratinate (Auro-Detoxin) at 50 mg gold every 14 days as maintenance dose
Number of subjects: 0
Study 30664604 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients undergoing TSA
Number of subjects: 931
Study 27815324 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 48
Study 27815324 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 48
Study 26426576 — intervention group
Group type: COMPARATOR
Intervention: Thoracic Epidural Analgesia (TEA)
Number of subjects: 50
Study 26426576 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral-to-Medial Continuous Transversus Abdominis Plane Block (LM-TAP)
Number of subjects: 50
Study 22750663 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group (paramedic teams supported by telemedicine)
Number of subjects: 16
Study 22750663 — intervention group
Group type: COMPARATOR
Intervention: Control group (physician staffed EMS teams)
Number of subjects: 16
Study 20573925 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-TIPS group (polytetrafluoroethylene‐covered stent within 72 hours after randomization)
Number of subjects: 63
Study 20573925 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy-EBL group (continuation of vasoactive-drug therapy, propranolol or nadolol, long-term endoscopic band ligation)
Number of subjects: 63
Study 20573925 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-TIPS group
Number of subjects: 63
Study 20573925 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy-EBL group
Number of subjects: 63
Study 18405061 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic REM sleep
Number of subjects: 11
Study 18405061 — intervention group
Group type: COMPARATOR
Intervention: Tonic REM sleep
Number of subjects: 11
Study 16807023 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg and Fluticasone propionate 500 microg Diskus, one inhalation twice daily for 12 weeks
Number of subjects: 46
Study 16807023 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg and Fluticasone propionate 500 microg Diskus plus 20 mg Enoxaparin administered subcutaneously once daily for 12 weeks
Number of subjects: 46
Study 12756427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0
Study 12756427 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 12756427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10997957 — intervention group
Group type: EXPERIMENTAL
Intervention: ANDRO‐6 (300 mg androstenedione, 150 mg DHEA, 750 mg Tribulus terrestris, 625 mg Chrysin, 300 mg Indole‐3‐carbinol, 540 mg Saw palmetto)
Number of subjects: 20
Study 10997957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8792252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometry
Number of subjects: 45
Study 1735264 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 120 mg three times daily
Number of subjects: 41
Study 1735264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 6694008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure spray irrigation of corn fields with partially treated wastewater
Number of subjects: 0
Study 6694008 — intervention group
Group type: COMPARATOR
Intervention: Control population with no direct exposure to wastewater
Number of subjects: 0
Study 6694008 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers cleaning spray nozzles
Number of subjects: 0
Study 30862817 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological language tasks
Number of subjects: 49
Study 30862817 — intervention group
Group type: COMPARATOR
Intervention: Semantic language tasks
Number of subjects: 49
Study 30552284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 51
Study 30552284 — intervention group
Group type: COMPARATOR
Intervention: Prednisone/prednisolone
Number of subjects: 51
Study 26933301 — intervention group
Group type: EXPERIMENTAL
Intervention: Driver Sleepiness Score (DSS)
Number of subjects: 73
Study 26933301 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 73
Study 26933301 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS and ESS administered together
Number of subjects: 73
Study 24562803 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIM risk score
Number of subjects: 12109
Study 22434095 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Number of subjects: 75
Study 22434095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 21183965 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic living donor nephrectomy
Number of subjects: 0
Study 21183965 — intervention group
Group type: COMPARATOR
Intervention: Open approach nephrectomy
Number of subjects: 0
Study 17660173 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with propofol and remifentanil
Number of subjects: 60
Study 17660173 — intervention group
Group type: COMPARATOR
Intervention: Desflurane and nitrous oxide
Number of subjects: 60
Study 17216221 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2 g/day for 3 months
Number of subjects: 30
Study 17216221 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 30
Study 14656737 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 10
Study 14656737 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin
Number of subjects: 10
Study 14656737 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 11034267 — intervention group
Group type: EXPERIMENTAL
Intervention: DigiTAb
Number of subjects: 16
Study 11034267 — intervention group
Group type: COMPARATOR
Intervention: Digibind
Number of subjects: 16
Study 9339678 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (carbamazepine, phenytoin, phenobarbital, or sodium valproate)
Number of subjects: 419
Study 9339678 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (treatment only after another seizure)
Number of subjects: 419
Study 9339678 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 419
Study 9339678 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 419
Study 9339678 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment and delayed treatment
Number of subjects: 419
Study 8449431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2
Number of subjects: 110
Study 8449431 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg PGE2
Number of subjects: 110
Study 8449431 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg PGE2
Number of subjects: 110
Study 8449431 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin requirement
Number of subjects: 110
Study 8449431 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall labor characteristics
Number of subjects: 110
Study 3535135 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous postoperative peritoneal lavage
Number of subjects: 79
Study 3535135 — intervention group
Group type: COMPARATOR
Intervention: No continuous postoperative peritoneal lavage (Control)
Number of subjects: 79
Study 31852711 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month dual antiplatelet therapy (DAPT)
Number of subjects: 2446
Study 31852711 — intervention group
Group type: COMPARATOR
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 2446
Study 28238742 — intervention group
Group type: COMPARATOR
Intervention: Vehicle/emollient control
Number of subjects: 30
Study 28238742 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Number of subjects: 30
Study 28238742 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate
Number of subjects: 30
Study 28238742 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 30
Study 28238742 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids (including clobetasol)
Number of subjects: 30
Study 26549156 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions
Number of subjects: 0
Study 26549156 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatments
Number of subjects: 0
Study 23751727 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS)
Number of subjects: 11
Study 23751727 — intervention group
Group type: COMPARATOR
Intervention: Control (non-CS)
Number of subjects: 11
Study 22229005 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of Vidrion-R (SS White) glass ionomer sealant
Number of subjects: 51
Study 22229005 — intervention group
Group type: COMPARATOR
Intervention: No clinical intervention (Control)
Number of subjects: 51
Study 19934290 — intervention group
Group type: COMPARATOR
Intervention: KRAS-mutated tumors
Number of subjects: 508
Study 19934290 — intervention group
Group type: COMPARATOR
Intervention: KRAS-wild-type tumors
Number of subjects: 508
Study 18063539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 18063539 — intervention group
Group type: COMPARATOR
Intervention: Granisetron
Number of subjects: 0
Study 14724047 — intervention group
Group type: EXPERIMENTAL
Intervention: Enforced smoking abstinence
Number of subjects: 12
Study 14724047 — intervention group
Group type: COMPARATOR
Intervention: Free smoking
Number of subjects: 12
Study 11258331 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative administration of Vazaprostan‐20 into the pulmonary artery
Number of subjects: 0
Study 11258331 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 0
Study 9440417 — intervention group
Group type: EXPERIMENTAL
Intervention: Braced intervals (HKAFO)
Number of subjects: 10
Study 9440417 — intervention group
Group type: COMPARATOR
Intervention: Unbraced intervals
Number of subjects: 10
Study 8059746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irrigation with automatic toothbrush (n = 16)
Number of subjects: 47
Study 8059746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irrigation with manual toothbrushing (n = 16)
Number of subjects: 47
Study 8059746 — intervention group
Group type: COMPARATOR
Intervention: Control group with continued normal toothbrushing (n = 15)
Number of subjects: 47
Study 3133716 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 150 mg nocte
Number of subjects: 39
Study 3133716 — intervention group
Group type: COMPARATOR
Intervention: Mianserin 30 mg nocte for 7 days, then 60 mg nocte for 5 weeks
Number of subjects: 39
Study 3133716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Trazodone and Mianserin)
Number of subjects: 39
Study 31648986 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated analysis of mutational, genomic, and expression profiles
Number of subjects: 223
Study 28089385 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted telephone interview
Number of subjects: 19
Study 28089385 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based motivational interview
Number of subjects: 19
Study 28089385 — intervention group
Group type: COMPARATOR
Intervention: Control group (untailored invitation and FOBT kit mailing)
Number of subjects: 19
Study 25500422 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation boost of 16 Gy
Number of subjects: 5318
Study 25500422 — intervention group
Group type: COMPARATOR
Intervention: No radiation boost
Number of subjects: 5318
Study 23161209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (HIV risk reduction interventions)
Number of subjects: 239
Study 23161209 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care with the PMTCT protocol (Control)
Number of subjects: 239
Study 21318637 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 88
Study 21318637 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic inspiratory resistive breathing (DR)
Number of subjects: 88
Study 21318637 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with diaphragmatic inspiratory resistive breathing (CE)
Number of subjects: 88
Study 21318637 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control (NE)
Number of subjects: 88
Study 19645912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile biofeedback (BF) applied to the lateral trunk during tandem gait practice.
Number of subjects: 0